Cargando…

First Outbreak Response Using an Oral Cholera Vaccine in Africa: Vaccine Coverage, Acceptability and Surveillance of Adverse Events, Guinea, 2012

BACKGROUND: Despite World Health Organization (WHO) prequalification of two safe and effective oral cholera vaccines (OCV), concerns about the acceptability, potential diversion of resources, cost and feasibility of implementing timely campaigns has discouraged their use. In 2012, the Ministry of He...

Descripción completa

Detalles Bibliográficos
Autores principales: Luquero, Francisco J., Grout, Lise, Ciglenecki, Iza, Sakoba, Keita, Traore, Bala, Heile, Melat, Dialo, Alpha Amadou, Itama, Christian, Serafini, Micaela, Legros, Dominique, Grais, Rebecca F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798604/
https://www.ncbi.nlm.nih.gov/pubmed/24147164
http://dx.doi.org/10.1371/journal.pntd.0002465
_version_ 1782287799073898496
author Luquero, Francisco J.
Grout, Lise
Ciglenecki, Iza
Sakoba, Keita
Traore, Bala
Heile, Melat
Dialo, Alpha Amadou
Itama, Christian
Serafini, Micaela
Legros, Dominique
Grais, Rebecca F.
author_facet Luquero, Francisco J.
Grout, Lise
Ciglenecki, Iza
Sakoba, Keita
Traore, Bala
Heile, Melat
Dialo, Alpha Amadou
Itama, Christian
Serafini, Micaela
Legros, Dominique
Grais, Rebecca F.
author_sort Luquero, Francisco J.
collection PubMed
description BACKGROUND: Despite World Health Organization (WHO) prequalification of two safe and effective oral cholera vaccines (OCV), concerns about the acceptability, potential diversion of resources, cost and feasibility of implementing timely campaigns has discouraged their use. In 2012, the Ministry of Health of Guinea, with the support of Médecins Sans Frontières organized the first mass vaccination campaign using a two-dose OCV (Shanchol) as an additional control measure to respond to the on-going nationwide epidemic. Overall, 316,250 vaccines were delivered. Here, we present the results of vaccination coverage, acceptability and surveillance of adverse events. METHODOLOGY/PRINCIPAL FINDINGS: We performed a cross-sectional cluster survey and implemented adverse event surveillance. The study population included individuals older than 12 months, eligible for vaccination, and residing in the areas targeted for vaccination (Forécariah and Boffa, Guinea). Data sources were household interviews with verification by vaccination card and notifications of adverse events from surveillance at vaccination posts and health centres. In total 5,248 people were included in the survey, 3,993 in Boffa and 1,255 in Forécariah. Overall, 89.4% [95%CI:86.4–91.8%] and 87.7% [95%CI:84.2–90.6%] were vaccinated during the first round and 79.8% [95%CI:75.6–83.4%] and 82.9% [95%CI:76.6–87.7%] during the second round in Boffa and Forécariah respectively. The two dose vaccine coverage (including card and oral reporting) was 75.8% [95%CI: 71.2–75.9%] in Boffa and 75.9% [95%CI: 69.8–80.9%] in Forécariah respectively. Vaccination coverage was higher in children. The main reason for non-vaccination was absence. No severe adverse events were notified. CONCLUSIONS/SIGNIFICANCE: The well-accepted mass vaccination campaign reached high coverage in a remote area with a mobile population. Although OCV should not be foreseen as the long-term solution for global cholera control, they should be integrated as an additional tool into the response.
format Online
Article
Text
id pubmed-3798604
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37986042013-10-21 First Outbreak Response Using an Oral Cholera Vaccine in Africa: Vaccine Coverage, Acceptability and Surveillance of Adverse Events, Guinea, 2012 Luquero, Francisco J. Grout, Lise Ciglenecki, Iza Sakoba, Keita Traore, Bala Heile, Melat Dialo, Alpha Amadou Itama, Christian Serafini, Micaela Legros, Dominique Grais, Rebecca F. PLoS Negl Trop Dis Research Article BACKGROUND: Despite World Health Organization (WHO) prequalification of two safe and effective oral cholera vaccines (OCV), concerns about the acceptability, potential diversion of resources, cost and feasibility of implementing timely campaigns has discouraged their use. In 2012, the Ministry of Health of Guinea, with the support of Médecins Sans Frontières organized the first mass vaccination campaign using a two-dose OCV (Shanchol) as an additional control measure to respond to the on-going nationwide epidemic. Overall, 316,250 vaccines were delivered. Here, we present the results of vaccination coverage, acceptability and surveillance of adverse events. METHODOLOGY/PRINCIPAL FINDINGS: We performed a cross-sectional cluster survey and implemented adverse event surveillance. The study population included individuals older than 12 months, eligible for vaccination, and residing in the areas targeted for vaccination (Forécariah and Boffa, Guinea). Data sources were household interviews with verification by vaccination card and notifications of adverse events from surveillance at vaccination posts and health centres. In total 5,248 people were included in the survey, 3,993 in Boffa and 1,255 in Forécariah. Overall, 89.4% [95%CI:86.4–91.8%] and 87.7% [95%CI:84.2–90.6%] were vaccinated during the first round and 79.8% [95%CI:75.6–83.4%] and 82.9% [95%CI:76.6–87.7%] during the second round in Boffa and Forécariah respectively. The two dose vaccine coverage (including card and oral reporting) was 75.8% [95%CI: 71.2–75.9%] in Boffa and 75.9% [95%CI: 69.8–80.9%] in Forécariah respectively. Vaccination coverage was higher in children. The main reason for non-vaccination was absence. No severe adverse events were notified. CONCLUSIONS/SIGNIFICANCE: The well-accepted mass vaccination campaign reached high coverage in a remote area with a mobile population. Although OCV should not be foreseen as the long-term solution for global cholera control, they should be integrated as an additional tool into the response. Public Library of Science 2013-10-17 /pmc/articles/PMC3798604/ /pubmed/24147164 http://dx.doi.org/10.1371/journal.pntd.0002465 Text en © 2013 Luquero et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Luquero, Francisco J.
Grout, Lise
Ciglenecki, Iza
Sakoba, Keita
Traore, Bala
Heile, Melat
Dialo, Alpha Amadou
Itama, Christian
Serafini, Micaela
Legros, Dominique
Grais, Rebecca F.
First Outbreak Response Using an Oral Cholera Vaccine in Africa: Vaccine Coverage, Acceptability and Surveillance of Adverse Events, Guinea, 2012
title First Outbreak Response Using an Oral Cholera Vaccine in Africa: Vaccine Coverage, Acceptability and Surveillance of Adverse Events, Guinea, 2012
title_full First Outbreak Response Using an Oral Cholera Vaccine in Africa: Vaccine Coverage, Acceptability and Surveillance of Adverse Events, Guinea, 2012
title_fullStr First Outbreak Response Using an Oral Cholera Vaccine in Africa: Vaccine Coverage, Acceptability and Surveillance of Adverse Events, Guinea, 2012
title_full_unstemmed First Outbreak Response Using an Oral Cholera Vaccine in Africa: Vaccine Coverage, Acceptability and Surveillance of Adverse Events, Guinea, 2012
title_short First Outbreak Response Using an Oral Cholera Vaccine in Africa: Vaccine Coverage, Acceptability and Surveillance of Adverse Events, Guinea, 2012
title_sort first outbreak response using an oral cholera vaccine in africa: vaccine coverage, acceptability and surveillance of adverse events, guinea, 2012
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798604/
https://www.ncbi.nlm.nih.gov/pubmed/24147164
http://dx.doi.org/10.1371/journal.pntd.0002465
work_keys_str_mv AT luquerofranciscoj firstoutbreakresponseusinganoralcholeravaccineinafricavaccinecoverageacceptabilityandsurveillanceofadverseeventsguinea2012
AT groutlise firstoutbreakresponseusinganoralcholeravaccineinafricavaccinecoverageacceptabilityandsurveillanceofadverseeventsguinea2012
AT cigleneckiiza firstoutbreakresponseusinganoralcholeravaccineinafricavaccinecoverageacceptabilityandsurveillanceofadverseeventsguinea2012
AT sakobakeita firstoutbreakresponseusinganoralcholeravaccineinafricavaccinecoverageacceptabilityandsurveillanceofadverseeventsguinea2012
AT traorebala firstoutbreakresponseusinganoralcholeravaccineinafricavaccinecoverageacceptabilityandsurveillanceofadverseeventsguinea2012
AT heilemelat firstoutbreakresponseusinganoralcholeravaccineinafricavaccinecoverageacceptabilityandsurveillanceofadverseeventsguinea2012
AT dialoalphaamadou firstoutbreakresponseusinganoralcholeravaccineinafricavaccinecoverageacceptabilityandsurveillanceofadverseeventsguinea2012
AT itamachristian firstoutbreakresponseusinganoralcholeravaccineinafricavaccinecoverageacceptabilityandsurveillanceofadverseeventsguinea2012
AT serafinimicaela firstoutbreakresponseusinganoralcholeravaccineinafricavaccinecoverageacceptabilityandsurveillanceofadverseeventsguinea2012
AT legrosdominique firstoutbreakresponseusinganoralcholeravaccineinafricavaccinecoverageacceptabilityandsurveillanceofadverseeventsguinea2012
AT graisrebeccaf firstoutbreakresponseusinganoralcholeravaccineinafricavaccinecoverageacceptabilityandsurveillanceofadverseeventsguinea2012